I-Mab (NASDAQ:NBP – Get Free Report) is one of 865 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare I-Mab to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Valuation & Earnings
This table compares I-Mab and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| I-Mab | $3.89 million | -$46.27 million | -4.58 |
| I-Mab Competitors | $675.01 million | $20.71 million | -12.88 |
I-Mab’s competitors have higher revenue and earnings than I-Mab. I-Mab is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| I-Mab | 1 | 0 | 1 | 0 | 2.00 |
| I-Mab Competitors | 9068 | 14544 | 43752 | 1426 | 2.55 |
I-Mab currently has a consensus target price of $9.00, suggesting a potential upside of 445.45%. As a group, “Biotechnology” companies have a potential upside of 65.93%. Given I-Mab’s higher possible upside, research analysts clearly believe I-Mab is more favorable than its competitors.
Institutional and Insider Ownership
38.4% of I-Mab shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares I-Mab and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| I-Mab | N/A | N/A | N/A |
| I-Mab Competitors | -9,113.66% | -118.64% | -32.27% |
Volatility & Risk
I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, I-Mab’s competitors have a beta of 1.22, suggesting that their average share price is 22% more volatile than the S&P 500.
Summary
I-Mab beats its competitors on 7 of the 13 factors compared.
About I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.
